{"title":"垂体腺瘤与核医学:最近的结果和正在进行的发展","authors":"Benjamin Chevalier , Arnaud Jannin , Stephanie Espiard , Emilie Merlen , Amandine Beron , Georges Lion , Marie-Christine Vantyghem , Damien Huglo , Christine Cortet-Rudelli , Clio Baillet","doi":"10.1016/j.lpm.2022.104144","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>In order to explore pituitary adenoma (PA), magnetic resonance imaging (MRI) remains the cornerstone. However, there are some limitations and MRI can be non-conclusive. The development of additional imaging modalities like nuclear medicine explorations may help to confirm PA diagnosis, guide management and follow up. Nuclear medicine uses </span>radiopharmaceuticals<span> for imaging with single photon emission computed tomography (SPECT), or </span></span>positron emission tomography<span> (PET), coupled to CT scan. Radiopharmaceuticals products target specific cellular elements which allow to explore several biological pathways. Nuclear medicine may also be used for therapeutic purposes and recent developments of approach based on Peptide Receptor<span><span> Radionuclide Therapy<span> (PRRT) for treatment of aggressive PA and pituitary carcinoma will be reviewed. Several </span></span>radiotracers have been studied in the context of PA, and the aim of this paper is to discuss their respective performances and clinical interest.</span></span></p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Pituitary adenoma & nuclear medicine: Recent outcomes and ongoing developments\",\"authors\":\"Benjamin Chevalier , Arnaud Jannin , Stephanie Espiard , Emilie Merlen , Amandine Beron , Georges Lion , Marie-Christine Vantyghem , Damien Huglo , Christine Cortet-Rudelli , Clio Baillet\",\"doi\":\"10.1016/j.lpm.2022.104144\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span><span>In order to explore pituitary adenoma (PA), magnetic resonance imaging (MRI) remains the cornerstone. However, there are some limitations and MRI can be non-conclusive. The development of additional imaging modalities like nuclear medicine explorations may help to confirm PA diagnosis, guide management and follow up. Nuclear medicine uses </span>radiopharmaceuticals<span> for imaging with single photon emission computed tomography (SPECT), or </span></span>positron emission tomography<span> (PET), coupled to CT scan. Radiopharmaceuticals products target specific cellular elements which allow to explore several biological pathways. Nuclear medicine may also be used for therapeutic purposes and recent developments of approach based on Peptide Receptor<span><span> Radionuclide Therapy<span> (PRRT) for treatment of aggressive PA and pituitary carcinoma will be reviewed. Several </span></span>radiotracers have been studied in the context of PA, and the aim of this paper is to discuss their respective performances and clinical interest.</span></span></p></div>\",\"PeriodicalId\":20530,\"journal\":{\"name\":\"Presse Medicale\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2022-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Presse Medicale\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0755498222000379\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Presse Medicale","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0755498222000379","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Pituitary adenoma & nuclear medicine: Recent outcomes and ongoing developments
In order to explore pituitary adenoma (PA), magnetic resonance imaging (MRI) remains the cornerstone. However, there are some limitations and MRI can be non-conclusive. The development of additional imaging modalities like nuclear medicine explorations may help to confirm PA diagnosis, guide management and follow up. Nuclear medicine uses radiopharmaceuticals for imaging with single photon emission computed tomography (SPECT), or positron emission tomography (PET), coupled to CT scan. Radiopharmaceuticals products target specific cellular elements which allow to explore several biological pathways. Nuclear medicine may also be used for therapeutic purposes and recent developments of approach based on Peptide Receptor Radionuclide Therapy (PRRT) for treatment of aggressive PA and pituitary carcinoma will be reviewed. Several radiotracers have been studied in the context of PA, and the aim of this paper is to discuss their respective performances and clinical interest.
期刊介绍：
Seule revue médicale "généraliste" de haut niveau, La Presse Médicale est l''équivalent francophone des grandes revues anglosaxonnes de publication et de formation continue.
A raison d''un numéro par mois, La Presse Médicale vous offre une double approche éditoriale :
- des publications originales (articles originaux, revues systématiques, cas cliniques) soumises à double expertise, portant sur les avancées médicales les plus récentes ;
- une partie orientée vers la FMC, vous propose une mise à jour permanente et de haut niveau de vos connaissances, sous forme de dossiers thématiques et de mises au point dans les principales spécialités médicales, pour vous aider à optimiser votre formation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
